Comprehensive Multiscale Characterization, in vivo Antioxidant Activity, and Subacute Toxicity Assessment of Pearl Powder.

Authors

Shaik Abdullah Nawabjan, G S Muthu Iswarya, Xinyue Yu, Krishnakumar Balu, Wa Tat Yan, Billy K C Chow

Published in

Journal of ethnopharmacology. Pages 122259. Aug 01, 2026. Epub Aug 01, 2026.

Abstract

Pearl powder has been used for centuries in Traditional Chinese Medicine for its detoxifying, regenerative, and anti-aging properties. This study evaluates the antioxidant efficacy and safety of pearl powder derived from Hong Kong pearl oysters (Pinctada imbricata).
The present study aimed to perform a comprehensive multiscale physicochemical characterization of pearl powder and to investigate it's in vivo antioxidant activity and subacute oral toxicity in C57BL/6J mice.
The powder was characterized using Raman spectroscopy, high-resolution transmission electron microscopy (HR-TEM), atomic force microscopy (AFM), BET surface area analysis, and X-ray photoelectron spectroscopy (XPS). In vivo antioxidant activity was assessed in male C57BL/6J mice (n = 12 per group) administered pearl powder orally at 250, 500, and 1000 mg/kg body weight daily for 4 weeks using FRAP, TEAC, ORAC, and MDA assays. A 28-day subacute toxicity study was conducted according to OECD Guideline 407 (500-1000 mg/kg b.w., n=5/sex/group).
Dose-dependent increases in FRAP, TEAC, and ORAC, together with reduced MDA levels, were observed especially in liver, kidney, and spleen (p < 0.05 to p < 0.0001). The toxicity study showed no mortality, clinical signs, or histopathological changes. Minor non-adverse biochemical variations lacked supporting pathology, establishing a No Observed Adverse Effect Level (NOAEL) of 500 mg/kg b.w.
These findings demonstrate pearl powder's potent antioxidant activity with a favorable safety profile, supporting its development as a natural therapeutic agent for oxidative stress-related conditions. Nonetheless, confirmation through clinical studies will be important to substantiate these preclinical observations.

PMID:
42542264
Bibliographic data and abstract were imported from PubMed on 02 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.